Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing
surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow
to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients
with prostate cancer may help doctors learn more about changes that occur in DNA after
treatment with sorafenib tosylate